Welcome to the 23rd Annual John Goldman E-Conference on
Chronic Myeloid Leukemia: Biology and Therapy!
Live Conference: October 7 – 10, 2021 CEST
On demand Conference: September 27 – November 10, 2021
Dear Colleagues and Friends,
REGISTRATION IS FREE OF CHARGE! Do not miss this opportunity to share science and education in the fields of Chronic Myeloid Leukemia, and to interact live with global experts directly from your home or office!
- Registration for the E-Conference, will give you access to the full scientific content of the meeting regardless of your time zone: The whole program will be broadcast live. All discussions and presentations requiring voting or live scientific interaction (roundtable, Meet the Expert sessions, Mentored Poster Walks) will be held live and all registered attendees who wish to participate are invited to join us online at the indicated CEST time. Pre-recorded lectures will be streamed live, followed by their live panel discussion (Question & Answer period) at the indicated CEST time.
See the PDF Live Program here.
- Also go to the recorded Program on Demand to view the sessions you may have missed and to revisit those you enjoyed the most, or to view them at your leisure before the live panel discussions.
The pre-recorded lectures will be available “on demand” as of September 27, 2021. The meeting’s full program, enriched by the many live elements recorded real time, will remain accessible to registered participants for 1 month after the meeting is over.
- Register for the live Meet the Expert sessions and bring your clinical case! Take the opportunity to receive personal guidance from global experts. Come prepared to turn on your webcam and microphone and to ask questions.
Space is limited and pre-registration is required. Please note that Meet the Expert sessions do not include a presentation by the session Leaders. They are designed to answer your questions and to provide expert guidance on specific questions. They are open to academic biologists and clinicians only. If you register for one of the sessions you will be expected to come prepared to ask at least one question. Webcam is compulsory.
Each Meet the Expert session will be organized for a maximum of 25-30 people (extra fee of 20€ per session).
- View the E-Posters and join the interactive Mentored Poster Walk.
- Read the E-Conference E-Book. A list of citations to guide further reading will also be available on the platform.
- Earn EBAH Continuing Medical Education (CME) credits for the time you spend furthering your knowledge and skills.
ABOUT THE PROGRAM:
Strong basic and clinical science:
Speakers at this meeting will present new, often unpublished data related to the (1) Biology of CML including the origin of BCR-ABL1, signal transduction, basis of disease progression, action of tyrosine kinase inhibitors and mechanisms underlying resistance to TKI, and (2) aspects of treatment including prediction and definition of responses, drugs used in combination, modern diagnostics and molecular monitoring, targeting residual stem cells, approaches to cure and treatment free remission.
The program will include:
- Special Lectures
- Keynote Lectures
- Oral Communications selected from Submitted Abstracts
- Workshops for Non-Clinical Scientists
- Mentored Poster Walks: Clinical and Biology
- ESH-iCMLf Clinical Symposium (topic to be announced)
- The John Goldman Prize Ceremony and Lecture
- The Janet Rowley Prize Ceremony and Lecture
- The iCMLf Prize Ceremony and Lecture
- The ESH John Goldman International Research Award ceremony and scientific presentation
Main Topics of the E-Conference:
- STEM CELLS AND THE MICROENVIRONMENT
- IMMUNOLOGY AND INFLAMMATION
- THE BIOLOGY OF BLAST PHASE
- NEW TREATMENT STRATEGIES
- TREATMENT-FREE REMISSION
- TREATMENT-FREE REMISSION – PREDICTIVE FACTORS
- TKI SAFETY
Upon completion of this CME activity, participants should:
- Understand current and new concepts of the signal transduction pathways involved in chronic myeloid leukemia (CML) and the mechanisms of action of tyrosine kinase inhibitors and other new agents.
- Have insight into the possible mechanisms of genomic instability that predisposes to formation of the BCR-ABL fusion gene and predispose also to disease progression and the consequences of such instability.
- Define a leukemia stem cell and its relationship to disease kinetics in so far as current knowledge permits.
- Evaluate the merits of various management decisions, e.g. how to start treatment for patients in the different phases of CML, how to assess success or failure of initial treatment, what approaches to consider for patients who have failed to respond well to initial treatment, including assessing the precise role of second and third generation TKIs and other non-molecular therapeutic approaches.
- Review the current recommendations and discuss current concepts and challenges of monitoring individual patients with hematologic, cytogenetic and molecular (RQ-PCR) methods.
- Assess the role of allogeneic stem cell transplantation in the management of CML.
- Critically evaluate the possible role of the different immunotherapeutic approaches in the treatment of CML.
- Discuss current data and ongoing research regarding treatment-free survival as an endpoint in CML management.
- Discuss patient reported outcomes and their role in the management of patients with CML.
We encourage you to visit the booths of our corporate partners in the virtual Exhibition Hall.
Registration is open to healthcare professionals worldwide. The registration is offered for free, as a gesture of solidarity during these difficult times.
– Access to the program on demand on September 27 – November 10, 2021
– Access to the live program on October 7 – 10, 2021 CEST
– Access to the Conference E-Book on September 27 – November 10, 2021
– Access to the E-Poster Area from September 27 – November 10, 2021
– Access to the Mentored E-Poster Walks
– Certificate of Attendance